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Introduction
Catheter bundles significantly reduce the rate of cathe-
ter-associated bloodstream infections. By continuous
release of chlorhexidine around the insertion site, the
use of antimicrobial devices demonstrated further
decrease of the rate of infection below 1 episodes/1000
catheter-days.
Objectives
To compared the fitness of use of (Biopatch®) and
(TegadermTM CHG).
Methods
All central venous catheters and arterial lines, inserted
and handled according to a written protocol in all
patients admitted to a mixed ICU of 5 units of 7 beds
(2000 admissions and 11’000 patients-days yearly) were
protected with antimicrobial devices. Biopatch® was used
over a 60 month period from 2009. Tegaderm™-CHG
was introduced in August 2011 for patients housed in 2
out 5 units and 18 months later replaced Biopatch® in all
units. Their fitness of use was compared using a struc-
tured questionnaire. The study design did not aim to
compare infection rates, which was about 0.3 episodes of
infections/1000 catheter days over the period of switch of
the devices.
Results
Health care workers answering the questionnaires were
specifically trained to provide care for ICU patients and
had followed internal training for catheter handling and
care, including specific sessions for the use of antimicrobial
devices. Experience captured by the questionnaire run on
several tens of individual catheter dressings in all possible
insertion sites. Compared to those reported after 60 months
of Biotpatch® use (n=24), the overall satisfaction signifi-
cantly increases after 14 months of Tegaderm™-CHG use
(n=42).Categories (in%) very good; good; average, bad
increased from 13, 46, 42, 0 to 74, 26, 0 and 0, respectively;
p<0.001. This was related to a significant improvement of
the ease of installation and of the ability of Tegaderm™-
CHG to cover beyond the insertion site protecting in most
cases also the area of fixation of the catheter to the skin.
Conclusion
Based on the significant improvement of fitness of use by
the healthcare workers, we decided to replace the Bio-
patch® by the Tegaderm-CHG™ in the dressing of all cen-
tral venous catheters and arterial lines for all ICU patients.
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